Trials / Completed
CompletedNCT03941548
Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
A Randomized Parallel-Group Study to Evaluate the Efficacy and Tolerability of Two Dosing Regimens of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Concert Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CTP-543 | Administered as 12 mg tablets. |
| DRUG | CTP-543 Matching Placebo | Administered as tablets to aid treatment masking. |
Timeline
- Start date
- 2019-05-24
- Primary completion
- 2020-04-10
- Completion
- 2020-04-10
- First posted
- 2019-05-08
- Last updated
- 2023-04-05
- Results posted
- 2023-04-05
Locations
12 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03941548. Inclusion in this directory is not an endorsement.